Financial crisis: rough times for pharma firms but industry will weather the impact
Monday, 13 October 2008- The current financial crisis poses challenges to big pharmaceutical and biotech companies, but compared with other industries the drug sector is likely to weather the financial crisis due to the necessity of their products and their diversified portfolio.
“If there’s a flight to safety...
Edited by: JV/Agencies
A case of ectopic dysplastic kidney and ectopic ureter diagnosed by MRI
Saturday, 11 October 2008 - This case study, published by Nature Clinical Practice Urology, describes a 14-year-old girl with continuous urinary incontinence after resection of a vaginal septum associated with uterus didelphys. The authors discuss the diagnostic procedures undertaken, and show that MRI was effective,...
Edited by: FGR
US, Finnish researchers identify cell protein-based treatment to suppress pain
Friday, 10 October 2008- Researchers at the University of North Carolina (UNC) at Chapel Hill School of Medicine and the University of Helsinki have identified a new therapeutic target for pain control, one that appears to be eight times more effective at suppressing pain than morphine.
The scientists studied...
Source: News agencies
Prostate cancer patient writes book on illness and donates book sales to urology clinic
Friday, 10 October 2008- For a 71-year-old British man who was diagnosed with prostate cancer, the bad news was not exactly a reason for him to fall into a deep depression. In fact, Mike Roberts turned it into something creative by writing his first poetry book.
Roberts, who was diagnosed in July 2007...
Source: News agencies
Prostate growth does not cause prostate specific antigen velocity
Friday, 10 October 2008 - Although prostate specific antigen velocity was proposed to increase the specificity of prostate specific antigen-based screening, there are little published data on the effect of differential prostate growth on prostate specific antigen velocity, underlines the Journal of Urology in its...
Edited by: FGR
BPH alpha blocker silodosin secures US FDA approval
Thursday, 9 October 2008- The alpha blocker drug silodosin (Rapaflo) has secured approval from the US Food and drug Administration (FDA). Silodosin is prescribed for the treatment of patients with Benign Prostatic Hyperplasia (BPH).
“Rapaflo is a novel product that provides strong efficacy and an exceptional...
Filed by: JV/PR
Europe remains in EAU’s core mission and strategy - Nurturing a European role is crucial amidst ‘global’ tendencies
Thursday, 9 October 2008 - Nurturing a European role must remain in the core mission of the European Association of Urology (EAU) in the face of a gradual shift to a more outwardlooking stance within the organisation. This was one of the general sentiments expressed by participants during the two-day annual EAU...
By: Joel Vega
A case of staghorn stones in a kidney with an ileal ureter treated by percutaneous nephrolithotomy
Wednesday, 8 October 2008 - In Nature Clinical Practice Urology (online publication in October 2008) Gao et al. present a 59-year-old man with complete staghorn calculi who had previously undergone ileal ureteral replacement. The patient was successfully treated with percutaneous nephrolithotomy. The authors emphasize...
Edited by: FGR
Aggressive promotion of medical tourism downplays potential legal risks
Wednesday, 8 October 2008- Medical ‘tourism’ remains a booming business in many developing countries due to the relatively cheaper medical costs they offer. But while the aggressive promotion highlights the savings and exotic destinations, it overlooks and downplays potential legal risks faced by patients...
Filed by: Joel Vega/agencies
Eli Lilly to buy ImClone for $6.5 billion
Tuesday, 7 October 2008- Eli Lilly has agreed to buy ImClone Systems Inc for $6.5 billion, outbidding Bristol-Myers Squibb Co.
“We feel that the Eli Lilly transaction vindicates our decision to oppose in 2006 a potential transaction in which the Company would have been sold at approximately $36 per share which the...
Source: PR/News agencies
